The most effective natural cholesterol-lowering treatment
Click on a box to see what we consider
the most effective natural Cholesterol treatment for you

WOMEN 39
AND UNDER		 MEN 39
AND UNDER		 WOMEN 40
AND UP		 MEN 40
AND UP
click here...click here...click here...click here...

New natural nutritional supplement lowers cholesterol by up to 30%

Based on extensive research and double-blind studies, the ingredients of this 100% natural nutritional supplement may produce the following results:

  • Lower elevated total cholesterol by up to 30%.
  • Lower unhealthy (LDL) cholesterol by up to 27%.
  • Increase healthy (HDL) cholesterol.
  • Lower triglycerides by up to 34%.
  • Improve LDL/HDL ratio (measure of the risk of heart disease) by up to 26%.
  • Reduce hardening of the arteries.
  • Reduce risk of chronic inflammation (lowers C-RP).
  • Reduce risk of blood clots.
  • Have no dangerous side effects.

What is Cholesterol and what are Triglycerides?

Cholesterol is a fatty substance that is vital for several of the body's functions. Too much cholesterol in your blood, however, can be harmful.

Triglycerides are another type of fat. A high level of triglycerides in the blood also increases the risk of developing heart disease.

Cholesterol and triglycerides are being transported around the body on special molecules called lipoproteins. Lipoproteins can either be LDL (low density lipoproteins) or HDL (high density lipoproteins). Triglycerides are being transported on VLDL (very low density lipoproteins).

The HDL cholesterol helps to bind and remove the cholesterol from the blood and is therefore called "healthy" cholesterol.

Why lower elevated cholesterol?

Today, cardiovascular disease is the number one cause of premature death, closely followed by cancer. It is a common belief among many doctors that the two most common reasons for premature death caused by heart disease are elevated cholesterol and inflammation.
The combination of a high level of cholesterol and chronic inflammation increases the risk of hardening of the arteries and at the same time increases the risk of blood clots.

According to the American Heart Association, 20% of the population suffers from elevated cholesterol and the subsequent risk of premature death.
Based on present knowledge, most health organisations recommend lowering cholesterol to acceptable levels (see below).

Until now, treatment of high cholesterol consisted of cholesterol lowering drugs (statins). Unfortunately, these drugs have several unpleasant side effects, and many individuals have had to interrupt their treatment because of these side effects.

A healthy diet is important for our health, but cholesterol in our diet only makes up for less than 20% of the total cholesterol in our body. The body itself produces the majority of the cholesterol independent of the diet. Therefore, it is important to focus on lowering the body's own production of cholesterol to achieve an effective reduction of the cholesterol.

Doctor's Natural new Ideal Cholesterol's effect is primarily focused on reducing the body's own production of cholesterol and at the same time reducing the risk of chronic inflammation and blood clots.

The ingredients in Doctor's Natural Ideal Cholesterol have been proven not only to reduce the body's own production of cholesterol but even to lower the level of other fatty substances, such as triglycerides without any side effects.

Recommended cholesterol levels:

Most international heart associations recommend lowering your cholesterol to less than:

Total cholesterol: 5 mmol/l
LDL: under 3 mmol/l
Triglycerides: 1-2 mmol/l

If you already suffer from hardening of the arteries or diabetes, it is recommended to lower your cholesterol to less than:

Total cholesterol: 4,5 mmol/l, og
LDL cholesterol: 2,5 mmol/l

Double-blind scientific study

A recent scientific study of the effect of the ingredients in Doctor's Natural Ideal Cholesterol was published in a peer-reviewed medical journal.

The purpose of this randomised, double-blind, placebo-controlled study was to examine the effect of the combination of certain citrus flavonoids (poly methoxylated flavones) (PMF) (270 mg/day) and tocotrienols, derived from palm oil fruit (30 mg/day).

All 120 subjects were between 19 and 65 years old and had a total cholesterol level of more than 230 mg/dl and a LDL cholesterol level of more than 155 mg/dl.

The subjects were either given a placebo or a combination of the natural citrus flavonoids and tocotrienols from palm fruits, in the amount of 150 mg twice a day (for further information about these ingredients, please see below).

Blood samples were taken after 4, 8 and 12 weeks. After only 4 weeks, those who were given the effective nutritional supplement experienced a significant fall in total cholesterol, LDL cholesterol, Apo-B and triglycerides, while the healthy HDL cholesterol increased.
The placebo group experienced no changes.

During the following 8 weeks, the cholesterol levels kept falling among the subjects who were given nutritional supplements whereas the levels in the placebo group remained unchanged.

After taking Doctor's Natural Ideal Cholesterol for 12 weeks:

  • Total cholesterol level was reduced by up to 30% compared to the placebo group.
  • The LDL cholesterol level was reduced by up to 27% compared to the placebo group.
  • The level of triglycerides was reduced by up to 34% compared to the placebo group.
  • Apo-lipoprotein B was reduced by up to 21% compared to the placebo group.
  • The HDL cholesterol level was increased by up to 4% compared to the placebo group.
  • All changes were statistically significant.

The scientist's conclusion

Approximately 80% of the body's cholesterol is produced in the liver and is more or less independent of the cholesterol introduced through the diet. This is why many people can't understand why they don't experience a change in their cholesterol levels after having made adjustments to their diet and having started exercising.

This fact has led to a dramatic increase in the sales of cholesterol lowering drugs known as "statins." Statins lower cholesterol efficiently but might also have dangerous side effects, such as damage to muscles and the liver. Unfortunately, they also impede the production of co-enzyme Q10, which is vital for the energy level in cells as well as the heart's ability to beat.

An increasing number of doctors and other persons suffering from elevated cholesterol have therefore searched for an alternative to these expensive and often harmful drugs.

Doctor's Natural Ideal Cholesterol is an effective, cheap and side effect-free alternative to these products.

Ref: Roza JM & al. EFFECT OF CITRUS FLAVONOIDS AND TOCOTRIENOLS ON SERUM CHOLESTEROL LEVELS IN HYPERCHOLESTEROLEMIC SUBJECTS. Altern Ther Health Med.; nov-dec. 13(6):44-48. 2007.

How does Doctor's Natural Ideal Cholesterol work?

In order to understand how Doctor's Natural Ideal Cholesterol works in the body it is necessary to have a basic understanding of our body's biochemistry. The following is a simplified explanation of how Doctor's Natural Ideal Cholesterol lowers cholesterol level:

  • Reduces elevated cholesterol by increasing the break down of HMG CoA reductase, which is a liver enzyme necessary for the body’s ability to produce cholesterol. Statins, however, impede the production of the HMG-CoA enzyme, which results in 200 times as many enzymes in just a couple of hours. This is considered one of the reasons for the adverse side effects.
  • Reduces an elevated concentration of unhealthy LDL cholesterol by, among other things, reducing the production of the Apo-lipoprotein B (ApoB) which is the structural protein necessary for the body’s production of LDL-cholesterol.
  • Lowers an elevated level of triglycerides by reducing the production of the enzyme diacylglycerol acetyl transferase (DGAT), which is necessary for the production of triglycerides.
  • Reduces the amount of fatty acids in the blood by increasing the level of hepato-cellular PPARα, which results in less fatty acids being transformed to triglycerides.
  • Does NOT reduce the production of co-enzyme Q10 (as seen in treatment with statins).
  • Does NOT increase the break down of important muscle proteins, which can damage the heart musculature and its ability to contract (as seen with the statins).
  • Recent animal studies also indicate that Doctor’s Natural Ideal Cholesterol has the following effects:
  • Reduces oxidation of the unhealthy LDL cholesterol, which is what especially makes the LDL cholesterol dangerous.
  • Reduces the risk of blood clot formation (reduces thrombosis).
  • Reduces the risk of damage to the heart in cases of reduced oxygen supply (ischemia).
  • Reduces hardening of the arteries (size and thickness of the plaques).
  • Reduces inflammation by reducing the production of pro-inflammatory cyclo-oxygenases and cytokines.

What does Doctor's Natural Ideal Cholesterol contain?

Cholesterol lowering patent

Two out of three ingredients in Doctor's Natural Ideal Cholesterol are derived from natural citrus flavones (poly methoxylated flavones, PMF) and natural palm tocotrienols. The third ingredient is derived from grape seeds and is called Resveratrol. This combination has a so-called synergistic effect and effectively lowers elevated levels of total cholesterol, LDL cholesterol and triglycerides.

Furthermore, this combination is able to increase the level of HDL cholesterol, reduce inflammation, have an anti-oxidant effect, reduce existing hardening of arteries and reduce the risk of thrombosis.

What are polymethoxylated flavones (PMFs)?

Natural polymethoxylated flavones are extremely bioactive and potent bioflavonoids found in certain citrus fruits. The flavones tangeretin and nobilitin, are two of the most frequent and potent flavones, which are also found in a healthy diet.

More than 25 years of research has shown that these natural nutrients in an exact dose and combination are beneficial for the heart.

Nobilitin and tangeretin have, in various studies, been proven to lower elevated LDL cholesterol levels by impeding the production of, amongst others, apolipoprotein B and triglycerides. Apolipoprotein B and triglycerides are today considered the primary building blocks of LDL cholesterol and constitute almost 90% of the LDL cholesterol complex.

In laboratory studies (in vitro), the combination of tangeretin and nobiletin has shown to be capable of reducing inflammation by equilibrating a series of important inflammatory cytokines (interleukin-6, interleukin 1-beta, etc).

Palm Tocotrionols

Palm tocotrienols and so-called tocopherols all belong to the vitamin E family and can be derived from the fruits of certain palm trees. Tocotrienols have anti-inflammatory qualities, and also, in combination with the polymethoxylated flavones, have been shown to break down HMG-CoA reductase.

HMG-CoA is a key enzyme in the liver’s production of cholesterol. Recent research shows that the biological production of the tocotrienols, amongst other things, may prevent and reduce the risk of developing various neurodegenerative and cardiovascular diseases.

Recent research also shows that the tocotrienols are being deposited in the aorta blood vessels at 100 times more the concentration than vitamin E. This indicates the enormous impact that these tocotrienols have on our risk of heart disease.

Resveratrol

Resveratrol is a natural substance found in grapes and other fruits and plants. Resveratrol has, in various studies, (at the correct dosage) shown to have many positive qualities, especially regarding cardiovascular disease. According to many scientists, the health benefits that red wine has on the heart is primarily due to its content of Resveratrol.
Resveratrol is proven to reduce oxidation of LDL-cholesterol. It is in fact not until the LDL-cholesterol has been oxidized that it becomes dangerous.

However, Resveratrol has also proven to be able to protect the heart cells from dying when they are being exposed to a reduced oxygen supply (Ischemia) due to hardening of the arteries.

Many studies show that Resveratrol can prevent the development of chronic inflammation, which promotes disease, especially for those with high cholesterol. Resveratrol reduces, among other things, the formation of various substances which provoke inflammation (e.g. cyclo oxygenase (COX-1), COX-2, hydroperoxidases, 5-lipooxygenases, interleukin-1 (IL-1) and IL-8).

Furthermore, Resveratrol reduces the risk of thrombosis by impeding the coagulation of blood plaques. It also has vasodilating (widening of blood vessels) effects.

Are there any side effects?

Various studies show that even at very high doses this supplement does not have any side effects, neither as symptoms nor in microscopic analysis of cells in the liver, kidney or spleen. Even at doses of 14.000 mg, the scientists could not report side effects (the daily dose of Ideal Cholesterol is 300 mg).

The subjects who were given the ingredients contained in Ideal Cholesterol in double blind studies had as few side effects as the subjects who were given placebos.

According to the Handbook of Pharmaceutical Drugs, cholesterol lowering drugs (statins) have various side effects: muscle pain, rash, stomach pain, insomnia, headache, muscle inflammation (myositis), break down of muscles (rhabdomyolysis), fatigue, reduced libido, impotence, liver damage and many more. Some scientific studies have even shown that the total risk of premature death is higher for those who took the pharmaceutical cholesterol lowering drugs (statins) compared to those who took placebos

References

  1. James M. Roza & al. EFFECT OF CITRUS FLAVONOIDS AND TOCOTRIENOLS ON SERUM CHOLESTEROL LEVELS IN HYPERCHOLESTEROLEMIC SUBJECTS. Altern Ther Health Med;13(6):44-48. Nov-dec 2007
  2. Ameer B, Weintraub RA, Johnson JV, Yost RA, Rouseff RL. Flavanone absorption after naringin, hesperidin, and citrus administration. Clin Pharmacol Ther. 1996 Jul;60(1):34-40.
  3. American Heart Association. What Your Cholesterol Levels Mean. Available at: www. Americanheart.org.  Accessed August 24, 2007.
  4. Aviram M. Rosenblat M. Gaitini D, Nitecki S, Hoffman A. Dornfield I., Volkova N, Presser D, Attias J, Liker H, Hayek T. Pomegranate juice consumption for 3 years by patents with carotid artery stenosis reduces cornmon carotid intima-media thickness, blood pressure and LDL oxidation. Clin Nutr. 2004. Jun23(3):423-433.
  5. Barter P. Treatment of dyslipidaemia in high-risk patients: too little, too late. Int J Clin Pract Suppl. 2002 Jul;(130):15-9.
  6. Bayer voluntarily withdraws Baycol. FDA Talk Papers T01-34. August 8, 2001.
  7. Black TM, Wang P, Maeda N, Coleman RA. Palm tocotrienols protect ApoE +/-mice from diet-induced atheroma formation. J Nutr. 2000;130(10):2420-2426.
  8. Bok SH, Lee SH, Park YB, Bae KH, Son KH, Jeong TS, Choi MS Plasma and hepatic cholesterol and hepatic activities of 3-hydroxy-3-methyl-glutaryl-CoA reductase and acyl CoA: cholesterol transferase are lower in rats fed citrus peel
  9. Borradaile NM, Carroll KK, Kurowska EM. Regulation of HepG2 cell apolipoprotein B metabolism by the citrus fl avanones hesperetin and naringenin. Lipids. 1999;34(6):591-598.
  10. Borradaile NM, de Dreu LE, Barrett PH, Behrsin CD, Huff MW. Hepatocyte apoB-containing lipoprotein secretion is decreased by the grapefruit flavonoid, naringenin, via inhibition of MTP-mediated microsomal triglyceride accumulation. Biochemistry. 2003 Feb 11;42(5):1283-91.
  11. Borradaile NM, de Dreu LE, Barrett PH, Huff MW. Inhibition of hepatocyte apoB secretion by naringenin: enhanced rapid intracellular degradation independent of reduced microsomal cholesteryl esters. J Lipid Res. 2002 Sep;43(9):1544-54.
  12. Borradaile, N.M., Carroll, K.K. and Kurowska, E.M. Regulation of apo B metabolism in HepG2 cells by the citrus flavanones hesperetin and naringenin. Lipids 34 (1999) 591-598.
  13. Borradaile, N.M., Carroll, K.K., and Kurowska, E.M., Regulation of HepG2 cell apolipoprotein B metabolism by the citrus flavones hesperitin and naringenin, Lipids, 34: 491-598, 1999
  14. Bors, W., Heller, W., Michel, C., and Saran, M., Flavonoids as antioxidants: determination of radical scavenging efficiencies, Method Enzymol., 186:343-355, 1990.
  15. Boudreau DM, Gardner JS, Malone KE, Heckbert SR, Blough DK, Daling JR. The association between 3-hydroxy-3-methylglu- taryl coenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. Cancer. 2004 Jun 1;100(11):2308-16.
  16. Brescianini S, Maggi S, Farchi G, Mariotti, et al. Low total cholesterol and increased risk of dying: are low levels clinical warning signs in the elderly? Results from the Italian Longitudinal Study on Aging. J Am Geriatr Soc. 2003 Jul;51(7):991-6.
  17. Brown MD, Jin L, Jien ML, et al. Lipid retention in the arterial wall of two mouse strains with different atherosclerosis suscep- tibility. J Lipid Res. 2004 Jun;45(6):1155-61.
  18. Buening MK, Chang RL, Huang MT, Fortner JG, Wood AW, Conney AH. Activation and inhibition of benzo(a)pyrene and aflatoxin B1 metabolism in human liver microsomes by naturally occurring flavonoid. Cancer Res. 1981 Jan;41(1):67-72.
  19. Cabezas Castro M, Liem A. The use of apolipoprotein B in clinical practice to determine the risk for atherosclerosis. Ned Tijdschr Geneeskd. 2003 Jul 26;147(30):1445-8.
  20. Cheeke, P.R., Nutrition and nutritional disease, in The Biology of the Laboratory Rabbit, Manning, P.J., Ringler, D.H., and Newcomer, C.E., Eds., Academic Press, San Diego, CA, 1994.
  21. Chiba H, Uehara M, Wu J, Wang X, Masuyama R, Suzuki K, Kanazawa K, Ishimi Y. Hesperidin, a citrus flavonoid, inhibits bone loss and decreases serum and hepatic lipids in ovariectomized mice. J Nutr. 2003 Jun;133(6):1892-7.
  22. Choi, J.S., Yokozawa, T., and Oura, H., Antihyperlipidemic effect of flavonoids from Prunus davidiana, J. Nat. Prod., 54:218-224, 1991.
  23. Cook NC, Samman S. Flavonoids—chemistry, metabolism, cardioprotective effects, and dietary sources. J Nutr Biochem. 1996;7(2):66-76.
  24. Datla KP, Christidou M, Widmer WW, Rooprai HK, Dexter DT. Tissue distribution and neuroprotective effects of citrus flavonoid tangeretin in a rat model of Parkinson's disease. Neuroreport. 2001 Dec 4;12(17):3871-5.
  25. Dixon JL, Ginsberg HN Regulation of hepatic secretion of apolipoprotein B containing lipoproteins: information obtained from cultured liver cells. J Lipid Res. 1993 Feb;34(2):167-79. Review 2
  26. Erlund I, Silaste ML, Alfthan G, Rantala M, Kesaniemi YA, Aro A. Plasma concentrations of the flavonoids hesperetin, naringenin and quercetin in human subjects following their habitual diets, and diets high or low in fruit and vegetables. Eur J Clin Nutr. 2002 Sep;56(9):891-8.
  27. Esserman L, Campbell M, Shoemaker M, Lobo M, Marx C, Benz C. Breast cancer inhibition by statins. J Clin Oncol. 2004 Jul 15;22(14 Suppl):1003.
  28. extract or a mixture of citrus bioflavonoids. J Nutr. 1999 Jun;129(6):1182-5.
  29. Farmer JA. Aggressive lipid therapy in the statin era. Prog Cardiovasc Dis 1998 Sep;41(2):71-94.
  30. Farnier M, Davignon J. Current and future treatment of hyperlipidemia: the role of statins. Am J Cardio .l 1998 Aug 27;82(4B):3J- 10J.
  31. Firenzuoli F, Gori L, Crupi A, Neri D. Flavonoids: risks or therapeutic opportunities? Recenti Prog Med. 2004 Jul-Aug;95(7- 8):345-51.
  32. Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci U S A. 1990 Nov;87(22):8931-4.
  33. Ford ES, Mokdad AH, Giles WH, Mensah GA. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey, 1999 to 2000. Circulation. 2003 May 6;107(17):2185-9.
  34. Gaist D, Jeppesen U, Andersen M, García Rodríguez LA, Hallas J, Sindrup SH. Statins and risk of polyneuropathy: A case-control study. Neurology 2002 May 14;58(9):1333-7.
  35. Gordon DA. Recent advances in elucidating the role of the microsomal triglyceride transfer protein in apolipo-protein B lipoprotein assembly. Curr Opin Lipidol. 1997;8(3):131-137.
  36. Gotto AM Jr. Lipid management in patients at moderate risk for coronary heart disease: insights from the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Med. 1999 Aug 23;107(2A):36S-39S.
  37. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. Clin Oncol. 2004 Jun 15;22(12):2388-94.
  38. Grundy SM, Cleeman JI, Bairey Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004 Jul 13;110(2):227-39.
  39. Guengerich FP, Kim DH. In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogenesis. 1990 Dec;11(12):2275-9.
  40. Gustafsson M, Flood C, Jirholt P, Boren J. Retention of atherogenic lipoproteins in atherogenesis. Cell Mol Life Sci. 2004 Jan;61(1):4-9.
  41. Guthrie N, Kurowska EM. Anti-cancer and cholesterol-lowering activities of tocotrienols. In: Wildman REC, ed. Handbook of Nutraceuticals and Functional Foods. Boca Raton, FL: CRC Press; 2000:269-280.
  42. Hansen, M.B., Nielsen, S.E., and Berg, K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Meth., 119:203-210, 1989.
  43. Hayes, K.C., Pronczuk, A. and Liang, J.S. Differences in the plasma transport and tissue concentrations of tocopherols and tocotrienols: Observations in humans and hamsters. P. Soc. Exp. Biol. Med. 202 (1993) 353-359.
  44. Herper M. Cholesterol guidelines a gift for Merck, Pfizer. Forbes. July 12, 2004.
  45. Horowitz, R.M, Gentili, B. Flavonoid constituents of Citrus. In Citrus Science and Technology; Nagy, S., Shaw, P.E., Veldhuis, M.K., Eds.; Avi Publishing Company, Inc.; Westport, CT, 1977; Vol 1, pp 397-426
  46. Iqbal J, Minhajuddin M, Beg ZH. Suppression of 7,12-dimethylbenz[alpha]anthracene-induced carcinogenesis and hypercholesterolaemia in rats by tocotrienol-rich fraction isolated from rice bran oil. Eur J Cancer Prev. 2003 Dec;12(6):447-53.
  47. Jamil H, Gordon DA, Eustice DC, et al. An inhibitor of the microsomal triglyceride transfer protein inhibits apoB secretion from HepG2 cells. Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11991-5.
  48. Jiang Z, Zheng X, Lytle RA, Higashikubo R, Rich KM. Lovastatin-induced up-regulation of the BH3-only protein, Bim, and cell death in glioblastoma cells. Neurochem. 2004 Apr;89(1):168-78.
  49. Jones PJH. MacDougali DE. Ntanios F, Vanstono CA. Dietary phytosterols as cholesterol lowering agents in humans. Can J Physiol PharmacoI. 1997. 75:217-227.
  50. Kamat JP, Sarma HD, Devasagayam TP, Naseratnam K and Basiron Y. Tocotrienols from palm oil as effective inhibitors of protein oxidation and lipid peroxidation in rat liver microsomes. Mol. Cell Biochem. 170:131-137, 1997.
  51. Kassirer JP. Why should we swallow what these studies say? Washington Post. August 1, 2004:B03. Available at: http://www.washingtonpost.com/wp-dyn/articles/A29456-2004Jul31.html. Accessed August 30, 2004.
  52. Katano H, Pesnicak L, Cohen JI. Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4960-5
  53. Kawaguchi, K., Mizuno, T., Aida, K., and Uchino, K. Hesperidin as an inhibitor of lipases from porcine pancreas and pseudomonas. Biosci. Biotech. Biochem.,61:102-104, 1997.
  54. Kawaii S, Tomono Y, Katase E, Ogawa K, Yano M. Antiproliferative activity of flavonoids on several cancer cell lines. Biosci Biotechnol Biochem. 1999 May;63(5):896-9.
  55. Khor, H.T., Chieng D.Y., and Ong, K.K. Tocotrienols inhibit liver HMG-CoA reductase activity in the guinea pig. Nutr. Res., 15:537:544, 1995.
  56. Kullo IJ, Gau GT, Tajik AJ. Novel risk factors for atherosclerosis. Mayo Clin Proc. 2000;75(4):369-380.
  57. Kumamoto H, Matsubara Y, Iizuka Y, Okamoto K, Yokoi K. Structure and hypotensive effect of fl avonoid glycosides in orange (Citrus sinensis OSBECK) peelings. Agric Biol Chem. 1986;50(3):781-783.
  58. Kurowska E, Manthey JA. Casaschi A, Theriault AG. Modulation of HepG2 cell net apolipoprotein B secretion by the citrus polymethoxyflavone. tangeretin. Lipids. 2004. 39:143-151
  59. Kurowska EM Determination of cholesterol-lowering potential of minor dietary components by measuring apolipoprotein B responses in HepG2 cells. Methods Enzymol. 2001;335:398-404.
  60. Kurowska EM, Banh C, Hasegawa S, Manners GD. Regulation of Apo B production in HepG2 cells by citrus limonoids. In: Berhow MA, Hasegawa S, eds. Citrus Limonoids:Functional Chemicals in Agriculture and Foods. ACS Symposium Series. Washington, CD:American Chemical Society; 2000:175-184.
  61. Kurowska EM, Borradaile NM. Hypocholesterolemic effects of dietary citrus juices in rabbits. Nutr Res. 2000;20:121-129.
  62. Kurowska EM, Laidlaw M, Barber J, et al. SytrinolTM, a novel cholesterol-lowering supplement. Paper presented at: Canadian Federation of Biological Sciences Annual Meeting; June 21-25, 2005; Guelph, Ontario, Canada.
  63. Kurowska EM, Manthey JA, Casaschi A, Theriault AG. Modulation of HepG2 cell net apolipoprotein B secretion by the citrus polymethoxyfl avone, tangeretin. Lipids. 2004;39(2):143-151.
  64. Kurowska EM, Manthey JA, Hasegawa S, Manners GD, Vandenberg TA. Cholesterol lowering effects of citrus juices, flavonoids and limonoids. Paper presented at: International Conference and Exhibition on Nutraceuticals and Functional Foods; September 13-17, 2000; Houston, TX.
  65. Kurowska EM, Manthey JA. Hypolipidemic effects and absorption of citrus polymethoxylated flavones in hamsters with diet-induced hypercholesterolemia. J Agric Food Chem. 2004 May 19;52(10):2879-86.
  66. Kurowska EM, Spence JD, Jordan J, Wetmore S, Freeman DJ, Piche LA,Serratore P. HDL-cholesterol-raising effect of orange juice in subjects with hypercholesterolemia. Am J Clin Nutr. 2000 Nov;72(5):1095-100.
  67. Kurowska EM. & al. Modulation of HepG2 cell net apolipoprotein B secretion by the citrus polymethoxyflavone, tangeretin. Lipids, 39(2): 143-51. 2004
  68. Kurowska, E.M. and Borradaile, N.M., Hypercholesterolemic effects of dietary citrus juices in rabbits, Nutr. Res., 20: 121-129, 2000.
  69. Kurowska, E.M., Hrabek-Smith, J.M., and Carroll, K.K., Compositional changes in serum lipoproteins during developing hypercholesterolemia induced in rabbits by cholesterol-free semipurified diets, Atherosclerosis, 78: 159-165, 1989.
  70. Kurowska, E.M., Morley, K. and Gapor, A. Role of tocotrienols from palm oil in regulation of apo B metabolism in HepG2 cells. Experimental Biology 99, Washington, DC, April 17-21, 1999.
  71. Kurowska, E.M., Morley, K., and Gapor, A. Regulation of apo B production in HepG2 cells by tocotrienols from palm oil. Proceedings, PORIM International Palm Oil Congress, Kuala Lumpur, Malaysia, 212-219, 1999.
  72. Lemos VS, Freitas MR, Muller B, Lino YD, Queiroga CE, Côrtes SF. Dioclein, a new nitric oxide-and endothelium-dependent vasodilator flavonoid. Eur J Pharmacol. 1999;386(1):41-46.
  73. Lin N, Sato T, Takayama Y, et al. Novel anti- inflammatory actions of nobiletin, a citrus polymethoxy flavonoid, on human synovial fibroblasts and mouse macrophages. Biochem Pharmacol. 2003 Jun 15;65(12):2065-71.
  74. Manach C, Morand C, Gil-Izquierdo A, Bouteloup-Demange C, Remesy C. Bioavailability in humans of the flavanones hesperidin and narirutin after the ingestion of two doses of orange juice. Eur J Clin Nutr. 2003 Feb;57(2):235-42.
  75. Manthey CL. Polvmethoxylated flavones derived from citrus suppress tumor necrosis factor-alpha expression by human rnonocytes. J Nat Prod. 1999, 62:441-444.
  76. Manthey JA, Grohmann K, Guthrie N. Biological properties of citrus flavonoids pertaining to cancer and infl ammation. Curr Med Chem. 2001;8(2):135-153.
  77. Manthey JA, Grohmann K, Guthrie N. Biological properties of citrus flavonoids pertaining to cancer and inflammation. Curr Med Chem. 2001 Feb;8(2):135-53.
  78. Manthey JA, Guthrie N. Antiproliferative activities of citrus flavonoids against six human cancer cell lines. J Agric Food Chem. 2002 Oct 9;50(21):5837-43.
  79. Maron DJ. Curr Atheroscler Rep. 2004 Jan;6(1):73-8.
  80. e J & al.  Synergistic inhibition of low-density lipoprotein oxidation by rutin, gamma-terpinene, and ascorbic acid. Phytomedicine, 11(2-3): 105-13. 2004
  81. Maron DJ. Flavonoids for reduction of atherosclerotic risk. Curr Atheroscler Rep. 2004 Jan;6(1):73-8.
  82. Mensink RP, van Houvelingen AC, Kromhout D, Hornstra G. A vitamin E concentrate rich in tocotrienols had no effect on serum lipids, lipoproteins, or platelet function in men with mildly elevated serum lipid concentrations. Am J Clin Nutr. 1999;69(2):213-219.
  83. Middleton E, Kandaswami C. Effects of flavonoids on immune and inflammatory cell functions. Biochem Pharmacol. 1992 Mar 17;43(6):1167-79.
  84. Milde J, Elstner EF, Grassmann J. Synergistic inhibition of low-density lipoprotein oxidation by rutin, gamma-terpinene, and ascorbic acid. Phytomedicine. 2004 Feb;11(2-3):105-13.
  85. Minagawa A, Otani Y, Kubota T, et al. The citrus flavonoid, nobiletin, inhibits peritoneal dissemination of human gastric carcinoma in SCID mice. Jpn J Cancer Res. 2001 Dec;92(12):1322-8.
  86. Monforte MT & al.  Biological effects of hesperidin, a Citrus flavonoid. (note II): hypolipidemic activity on experimental hypercholesterolemia in rat. Farmaco, 50(9): 595-9. 1995
  87.  Monforte MT, Trovato A, Kirjavainen S, Forestieri AM, Galati EM, Lo Curto RB. Biological effects of hesperidin, a citrus flavonoid. (note II): hypolipidemic activity on experimental hypercholesterolemia in rat. Farmaco. 1995 Sep;50(9):595-9.
  88.  Mukhtar H, Das M, Khan WA, Wang ZY, Bik DP, Bickers DR. Exceptional activity of tannic acid among naturally occurring plant phenols in protecting against 7,12-dimethyl- benz(a) anthracene-, benzo(a)pyrene-, 3- methylcholanthrene-, and N-methyl-N- nitrosourea-induced skin tumorigenesis in mice. Cancer Res. 1988 May 1;48(9):2361-5.
  89.  Murakami A, Koshimizu K, Ohigashi H, Kuwahara S, Kuki W, Takahashi Y, Hosotani K, Kawahara S, Matsuoka Y. Characteristic rat tissue accumulation of nobiletin, a chemopreventive polymethoxyflavonoid, in comparison with luteolin. Biofactors. 2002;16(3-4):73-82.
  90.  Murakami A, Kuwahara, S., Takahashi Y , Ito, C., Furukawa, H., Ju-Ichi, M. In Vitro absorption and metabolism of nobiletin, a chemopreventive polymethoxyflavonoid in citrus fruits. Biosci., Biotechnol., Biochem. 2001. 65. 194-197.
  91.  Murakami A, Nakamura Y, Ohto Y, et al. Suppressive effects of citrus fruits on free radical generation and nobiletin, an anti- inflammatory polymethoxyflavonoid. Biofactors. 2000;12(1-4):187-92.
  92.  Murakami A, Nakamura Y, Torikai K, et al. Inhibitory effect of citrus nobiletin on phor- bol ester-induced skin inflammation, oxidative stress, and tumor promotion in mice. Cancer Res. 2000 Sep 15;60(18):5059-66.
  93.  Nash IS, Mosca L, Blumenthal RS, Davidson MH, Smith SC Jr, Pasternak RC. Contemporary awareness and understanding of cholesterol as a risk factor: results of an American Heart Association national survey. Arch Intern Med. 2003 Jul 14;163(13):1597- 600.
  94.  National Health and Nutrition Examination Study III (NHANES III, 1988–94) (CDC) NCHS.
  95.  Nawarskas JJ. HMG-CoA reductase inhibitors and coenzyme Q10. Cardiol Rev.2005;13(2):76-79.
  96.  Nelson EK. The occurrence of a pentamethyl flavonol in tangerine peel. J Am Chem Soc. 1934;56:1392.
  97.  Nestet P. Cehun M, Pomeroy S, Abbey M, Weldon G. ChotesteroI-lowering effects of plant sterol esters and non-esterified stanols in margarine, butter and low-fat foods. Eur J Clin Nutr 2001. 55:1084-1090.
  98.  Newaz MA, Nawal NN. Effect of gamma-tocotrienol on blood pressure, lipid peroxidation and total antioxidant status in spontaneously hypertensive rats (SHR). Clin Exper Hypertens. 1999;21(8):1297-1313.
  99.  Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA. 1996 Jan 3;275(1):55-60.
  100.  Nielsen SE, Breinholt V, Cornett C, Dragsted LO Biotransformation of the citrus flavone tangeretin in rats. Identification of metabolites with intact flavane nucleus. Food Chem Toxicol. 2000 Sep;38(9):739-46.
  101.  O'Leary KA, de Pascual-Tereasa S, Needs PW, Bao YP, O'Brien NM, Williamson G. Effect of flavonoids and vitamin E on cyclooxygenase-2 (COX-2) transcription. Mutat Res. 2004 Jul 13;551(1-2):245-54.
  102.  Onder G, Landi F, Volpato S, et al. Serum cholesterol levels and in-hospital mortality in the elderly. Am J Med. 2003 Sep;115(4):265-71.
  103.  Ong AS, Goh SH. Palm oil: a healthful and cost-effective dietary component. Food Nutr Bull. 2002 Mar;23(1):11-22.
  104.  Ornish D. Lower cholesterol without drugs. Washington Post. August 8, 2004:B07.
  105.  Osiecki H. The role of chronic inflammation in cardiovascular disease and its regulation by nutrients. Altern Med Rev. 2004 Mar;9(1):32-53.
  106.  Parker RA, Pearce BC, Clark RW, Gordon DA, Wright JJ. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem. 1993;268(15):11230-11238.
  107.  Pearce BC, Parker RA, Deason ME, Quereshi AA, Wright JJ. Hypercholesterolemic activity of synthetic and natural tocotrienols. J Med Chem. 1992;35(20):3595-3606.
  108.  Perreault S, Hamilton VH, Lavoie F, Grover S. Treating hyperlipidemia for the primary prevention of coronary disease. Are higher doses of lovastatin cost-effective? Arch Intern Med 1998 Feb 23;158(4):375-81.
  109.  Poynter J, Rennert G, Bonner J, et al. HMG CoA reductase inhibitors and the risk of colorectal cancer. Proceedings from the 40th annual meeting of the American Society of Clinical Oncology. New Orleans, LA. June 2004.
  110.  Pullinger CR, Kane JP, Malloy MJ. Primary hypercholesterolemia: genetic causes and treatment of five monogenic disorders. Expert Rev Cardiovasc Ther. 2003 May;1(1):107-19.
  111.  Quereshi AA, Bradlow BA, Salser WA, Brace LD. Novel tocotrienols of rice bran modulate cardiovascular disease risk parameters of hypercholesterolemic humans. Nutr Biochem. 1997;8(5):290-298.
  112.  Quereshi, A.A., Bradlow, B.A., Salser, W.A., and Brace, L.D. Novel tocotrienols of rice bran modulate cardiovascular disease risk parameters of hypercholesterolemic humans. J. Nutr. Biochem., 8:290-298, 1997.
  113.  Quereshi, A.A., Pearce, B.C., Nor, R.M., Gapor, A., Peterson, D.M. and Elson. C.E. Dietary !-tocopherol attenuates the impact of "-tocotrienol on hepatic 3-hydroxy-3-methylglutaryl coenzyme a reductase activity in chickens. J. Nutr., 126:389-394, 1996.
  114.  Quereshi, A.A., Quereshi, N., Hasler-Rapacz, J.O. et al. Dietary tocotrienols reduce concentrations of plasma cholesterol, apolipoprotein B, tromboxane B2, and platelet factor 4 in pigs with inherited hyperlipidemias. Am. J. Clin. Nutr. 53 (1991) 1042S-1046S.
  115.  Quereshi, A.A., Quereshi, N., Wright J.J.K., Shen, Z., Kramer, G., Gapor, A., Chong, Y.H., DeWitt, G., Ong, A.S.H., Peterson, D.M., and Bradlow, B.A. Lowering of serum cholesterol in hypercholesterolemic humans by tocotrienols (palmvitee). Am. J. Clin. Nutr., 53:1021S-1026S, 1991.
  116.  Quereshi, N. and Quereshi, A.A. Tocotrienols: Novel hypocholesterolemic agents with antioxidant properties. In: Vitamin E in Health and Disease, Packer L. and Fuchs, J. (eds.) Marcel Dekker, Inc., New York 1993, 247-267.
  117.  Qureshi AA, Bradlow BA, Brace L, et al. Response of hypercholesterolemic subjects to administration of tocotrienols. Lipids. 1995; 30(12):1171-1177.
  118.  Qureshi AA, Sami SA, Salser WA, Khan FA. Dose-dependent suppression of serum cholesterol by tocotrienol-rich fraction (TRF25) of rice bran in hypercholesterolemic humans. Atherosclerosis. 2002 Mar;161(1):199-207.
  119.  Ricks D, Rabin R. Panel’s ties to drugmakers not cited in new cholesterol guidelines. Newsday. July 15, 2004.
  120.  Shannon J, Garzotto M, Palma AJ. Statin use and prostate cancer risk. J Clin Oncol. 2004 Jul 15;22(14 Suppl):4596.
  121.  Shin, Y.W., Bok, S.H., Jeong, T.S., Bae, K.H., Jeoung, N.H., Choi, M.S., Lee, S.H. and Park, Y.B. Hypocholesterolemic effect of naringin associated with hepatic cholesterol regulating enzyme changes in rats. Int. J. Vitam. Nutr. Res. 69 (1999) 341-347. 5
  122.  Siess MH, Guillermic M, Le Bon AM, Suschetet M. Induction of monooxygenase and transferase activities in rat by dietary administration of flavonoids. Xenobiotica. 1989 Dec;19(12):1379-86.
  123.  Silver M, Langsjoen P, Szabo S, Patil H, Zelinger A. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. AmJ Cardiol. 2004;94(10):1306-1310.
  124.  Smogorzewski M. The myopathy of statins. J Ren Nutr. 2005;15(1):87-93.
  125.  Spencer JP, Chowrimootoo G, Choudhury R, Debnam ES, Srai SK, Rice-Evans C. The small intestine can both absorb and glucuronidate luminal flavonoids. FEBS Lett. 1999 Sep 17;458(2):224-30
  126.  Steyer TE, King DE, Mainous AG 3rd, Gilbert G. Use of nutritional supplements for the prevention and treatment of hypercholesterolemia. Nutrition. 2003 May;19(5):415-8.
  127.  Sun W, Yan Y, Dong F. Progression of tocotrienols. Wei Sheng Yan Jiu. 2004 Mar;33(2):243-5.
  128.  Theriault A, Chao JT, Wang Q, Gapor A, Adeli K. Tocotrienol: a review of its therapeutic potential. Clin Biochem. 1999;32(5):309-319.
  129.  Theriault, A., Wang, Q., Gapor, A., and Adeli, K. Effects of "-tocotrienol on apoB synthesis, degradation, and secretion in HepG2 cells. Arterioscler. Tromb.Vac. Biol., 19:714-712, 1999.
  130.  Thrift, R.N., Forte, T.M., Cahoon, B.E., and Shore, V.G., Characterization of lipoprotein produced by the human liver cell line HepG2, under defined conditions, J. Lipid Res., 27: 236-250, 1986.
  131.  Tomeo AC, Geller M, Watkins TR, Gapor A and Bierenbaum ML. Antioxidant effects of tocotrienols in patients with hyperlipidemia and carotid stenosis. Lipids 30:1179-1183, 1995.
  132.  Tseng KF. Nobiletin. Part I., an oil extracted by cold methyl alcohol from Citrus nobilis, Lour, affords nobiletin, a hexam- ethoxyflavone containing a veratryl nucleus. Chem Soc. 1938;1003-4.
  133.  Verma AK, Johnson JA, Gould MN, Tanner MA. Inhibition of 7,12- dimethylbenz(a)anthracene and N-nitro somethylurea induced rat mammary cancer by dietary flavonol quercetin. Cancer Res. 1988 Oct 15;48(20):5754-8.
  134.  Wald NJ, Law MR. Serum cholesterol and ischaemic heart disease. Atherosclerosis. 1995 Dec;118 Suppl:S1-5.
  135.  Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improve- ment in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001 Dec 15;358(9298):2026-33.
  136.  Walldius G, Jungner I. Apolipoproteins are new and better risk indicators of myocardial infarction. Lakartidningen. 2004 Mar 25;101(13):1188-94.
  137.  Watkins, T., Lenz, P., Gapor, A., Struck, M., Tomeo, A., and Bierenbaum, M. - Tocotrienol as a hypocholesterolemic and antioxidant agent in rats fed atherogenic diet. Lipids 28:1113-1118, 1993.
  138.  Weverling-Rijnsburger AW, Jonkers IJ, van Exel E, Gussekloo J, Westendorp RG. High- density vs low-density lipoprotein choles- terol as the risk factor for coronary artery disease and stroke in old age. Arch Intern Med. 2003 Jul 14;163(13):1549-54.
  139.  Wilcox LJ, Borradaile NM, de Dreu LE, Huff MW. Secretion of hepatocyte apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTP. J Lipid Res. 2001 May;42(5):725-34.
  140.  Wilcox, L.J., Borradaile, N.M., Kurowska, E.M. Telford, D.E., and Huff, M.W., Naringenin, a citrus flavonoids, markedly decreases apoB secretion in HepG2 cells and inhibits acyl CoA:cholesterol acyltransferase, Circulation, 98: 1-537, 1998.
  141.  Williams K, Sniderman AD, Sattar N, D’Agostino R Jr, Wagenknecht LE, Haffner SM. Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2003 Nov 11;108(19):2312-6.
  142.  Wolfe SM. Dangers of rosuvastatin identified before and after FDA approval. Lancet. 2004 Jun 26;363(9427):2189-90.
  143.  Your Guide to Lowering Your Cholesterol With TLC. Washington, DC: US Dept of Health and Human Services; 2005. NIH publication 06-5235.